Skip to main content
NCBI home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 2000 Nov;91(11):1154–1160. doi: 10.1111/j.1349-7006.2000.tb00899.x

Apoptotic Cytotoxic Effects of a Histone Deacetylase Inhibitor, FK228, on Malignant Lymphoid Cells

Makoto Murata 1, Masayuki Towatari 1, Hiroshi Kosugi 1, Mitsune Tanimoto 1, Ryuzo Ueda 3, Hidehiko Saito 1, Tomoki Naoe 2,✉
PMCID: PMC5926292  PMID: 11092981

Abstract

Histone deacetylases are promising targets for cancer treatment. Here we studied the in vitro effects of a potent histone deacetylase inhibitor, FK228 (formerly FR901228), on human leukemia/lymphoma cells and cell lines compared with normal hematopoietic cells. In a lymphoma cell line, Raji, a nanomolar concentration of FK228 induced G1 arrest and/or apoptotic cell death, depending on the concentration and exposure time. Growth of lymphoid cell lines including Raji (N=13) was inhibited by 50% (IC50) after 2‐day treatment at concentrations of 0.83 to 1.87 ng/ml. Viability of clinical samples from patients with acute lymphoblastic leukemia was decreased by 50% at 0.78±0.46 ng/ml, whereas the IC50 values for normal mononuclear cells from peripheral blood and bone marrow were 2.3±0.96 and 7.8±1.0 ng/ml, respectively. The IC50 values for normal progenitor cells were 3.1, 4.4 and 7.8 ng/ml for BFU‐E, CFU‐GM and CFU‐Mix, respectively. Expression levels of HDAC‐1 and HDAC‐3 proteins, which varied among cell lines, but were stable during the treatment with FK228, did not correlate with the sensitivity to FK288. This novel agent might be useful in the treatment of lymphoid malignancies, because the above concentrations are clinically achievable in vivo according to a recent clinical study.

Keywords: Leukemia, Lymphoma, Apoptosis, Histone deacetylase inhibitor, FK228

Full Text

The Full Text of this article is available as a PDF (118.5 KB).

REFERENCES

  • 1. ) Wolffe , A. P.Histone deacetylase: a regulator of transcription . Science , 272 , 371 – 372 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Strahl , B. D. and Allis , C. D.The language of covalent histone modifications . Nature , 403 , 41 – 45 ( 2000. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Giles , R. H. , Peters , D. J. and Breuning , M. H.Conjunction dysfunction: CBP/p300 in human disease . Trends Genet. , 14 , 178 – 183 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) McCaffrey , P. G. , Newsome , D. A. , Fibach , E. , Yoshida , M. and Su , M. S.Induction of gamma‐globin by histone deacetylase inhibitors . Blood , 90 , 2075 – 2083 ( 1997. ). [PubMed] [Google Scholar]
  • 5. ) Yoshida , M. , Kijima , M. , Akita , M. and Beppu , T.Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A . J. Biol. Chem. , 265 , 17174 – 17179 ( 1990. ). [PubMed] [Google Scholar]
  • 6. ) Kijima , M. , Yoshida , M. , Sugita , K. , Horinouchi , S. and Beppu , T.Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase . J. Biol. Chem. , 268 , 22429 – 22435 ( 1993. ). [PubMed] [Google Scholar]
  • 7. ) Finnin , M. S. , Donigian , J. R. , Cohen , A. , Richon , V. M. , Rifkind , R. A. , Marks , P. A. , Breslow , R. and Pavletich , N. P.Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors . Nature , 401 , 188 – 193 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) Hoshikawa , Y. , Kwon , H. J. , Yoshida , M. , Horinouchi , S. and Beppu , T.Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines . Exp. Cell Res. , 214 , 189 – 197 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 9. ) Sowa , Y. , Orita , T. , Minamikawa , S. , Nakano , K. , Mizuno , T. , Nomura , H. and Sakai , T.Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites . Biochem. Biophys. Res. Commun. , 241 , 142 – 150 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 10. ) Medina , V. , Edmonds , B. , Young , G. P. , James , R. , Appleton , S. and Zalewski , P. D.Induction of caspase‐3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c‐dependent pathway . Cancer Res. , 57 , 3697 – 3707 ( 1997. ). [PubMed] [Google Scholar]
  • 11. ) He , L. Z. , Guidez , F. , Tribioli , C. , Peruzzi , D. , Ruthardt , M. , Zelent , A. and Pandolfi , P. P.Distinct interactions of PML‐RARalpha and PLZF‐RARalpha with co‐repressors determine differential responses to RA in APL . Nat. Genet. , 18 , 126 – 135 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 12. ) Warrell , R. , Jr. , He , L. Z. , Richon , V. , Calleja , E. and Pandolfi , P. P.Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase . J. Natl. Cancer Inst. , 90 , 1621 – 1625 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 13. ) Kosugi , H. , Towatari , M. , Hatano , S. , Kitamura , K. , Kiyoi , H. , Kinoshita , T. , Tanimoto , M. , Murate , T. , Kawashima , K. , Saito , H. and Naoe , T.Histone deacetylase inhibitors are potent inducer/enhancers of differentiation in acute myeloid leukemia: a new approach to anti‐leukemia therapy . Leukemia , 13 , 1316 – 1324 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 14. ) Kitamura , K. , Hoshi , S. , Koike , M. , Kiyoi , H. , Saito , H. and Naoe , T.Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all‐trans retinoic acid . Br. J. Haematol. , 108 , 696 – 702 ( 2000. ). [DOI] [PubMed] [Google Scholar]
  • 15. ) Bernhard , D. , Ausserlechner , M. J. , Tonko , M. , Loffler , M. , Hartmann , B. L. , Csordas , A. and Kofler , R.Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts . FASEB J. , 13 , 1991 – 2001 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 16. ) Ueda , H. , Nakajima , H. , Hori , Y. , Fujita , T. , Nishimura , M. , Goto , T. and Okuhara , M.FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico‐chemical and biological properties, and antitumor activity . J. Antibiot. (Tokyo) , 47 , 301 – 310 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 17. ) Nakajima , H. , Kim , Y. B. , Terano , H. , Yoshida , M. and Horinouchi , S.FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor . Exp. Cell Res. , 241 , 126 – 133 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 18. ) Ueda , H. , Manda , T. , Matsumoto , S. , Mukumoto , S. , Nishigaki , F. , Kawamura , I. and Shimomura , K.FR 901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice . J. Antibiot. (Tokyo) , 47 , 315 – 323 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 19. ) Byrd , J. C. , Shinn , C. , Ravi , R. , Willis , C. R. , Waselenko , J. K. , Flinn , I. W. , Dawson , N. A. and Grever , M. R.Depsipeptide (FR901228): a novel therapeutic agent with selective,. in vitro activity against human B‐cell chronic lymphocytic leukemia cells . Blood , 94 , 1401 – 1408 ( 1999. ). [PubMed] [Google Scholar]
  • 20. ) Marshall , J. L. , Dahut , W. L. , Rizvi , N. , Wainer , L. W. , Chassaing , C. , Figuierra , M. and Hawkins , M. J.Phase I trial and pharmacokinetics analysis of depsipeptide in patients with advanced cancer . Proc. 35th Annu. Meet. ASCO ( 1998. ).
  • 21. ) Freedman , L. P.Increasing the complexity of coactivation in nuclear receptor signaling . Cell , 97 , 5 – 8 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 22. ) Gu , W. and Roeder , R. G.Activation of p53 sequence‐specific DNA binding by acetylation of the p53 C‐terminal domain . Cell , 90 , 595 – 606 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 23. ) Sowa , Y. , Orita , T. , Minamikawa‐Hiranabe , S. , Mizuno , T. , Nomura , H. and Sakai , T.Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor . Cancer Res. , 59 , 4266 – 4270 ( 1999. ). [PubMed] [Google Scholar]
  • 24. ) Glick , R. D. , Swendeman , S. L. , Coffey , D. C. , Rifkind , R. A. , Marks , P. A. , Richon , V. M. and La Quaglia , M. P.Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma . Cancer Res. , 59 , 4392 – 4299 ( 1999. ). [PubMed] [Google Scholar]
  • 25. ) Look , A. T.Oncogenic transcription factors in the human acute leukemias . Science , 278 , 1059 – 1064 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 26. ) Chaudhary , P. M. and Roninson , I. B.Expression and activity of P‐glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells . Cell , 66 , 85 – 94 ( 1991. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES